BTIG Targets 50% Upside for 2 Gene Editing Stocks

NTLA is still headed toward a third straight weekly loss

by Karee Venema

Published on Feb 8, 2019 at 11:27 AM

BTIG is chiming in on healthcare names today, and for gene editing stocks Editas Medicine Inc (NASDAQ:EDIT) and Intellia Therapeutics Inc (NASDAQ:NTLA), this resulted in fresh "buy" ratings and impressive price targets. Both EDIT and NTLA are capitalizing on the bull notes, though the latter is still pacing toward a third straight weekly loss.

EDIT Put Options Have Gained in Popularity

At last check, Editas Medicine is trading up 1.3% at $19.69. The stock has been trending lower since its March 9 record high of $45.02, with a recent rally off its Dec. 24 16-month low of $17.80 running into a wall at its 80-day moving average. Since then, the shares gapped 20% lower on Jan. 22 in the wake of a C-suite shakeup, and plunged 7.9% yesterday after disappointing trial data from a pair of biotechs.

edit stock daily chart on feb 8

Nevertheless, BTIG set a $30 price target on EDIT stock -- a 55% premium to last night's close. This bullish bias is shared by the broader analyst community, but options traders have taken a more bearish stance toward the equity.

At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the security's 10-day put/call volume ratio of 0.43 ranks in the 82nd annual percentile, meaning puts have been bought to open relative to calls at a quicker-than-usual clip. The January 2020 12.50-strike put is home to peak open interest, and data from Trade-Alert suggests the bulk of these options were purchased.

NTLA Stock is Stuck Between Key Technical Levels

For Intellia Therapeutics, BTIG set a price target of $20, representing expected upside of 56.4% to Thursday's close. After falling as much as 0.7% earlier, NTLA stock has since swung up 2.3% to trade at $13.08. The shares remain down 60% from their Sept. 20 annual high of $32.95 and are headed toward a third straight weekly loss, and have recently been stuck between support near $12.70 and resistance at their 40-day moving average.

ntla stock daily chart on feb 8

Analysts are mostly upbeat when it comes to NTLA. While four of seven maintained a "buy" or better rating at last night's close, the average 12-month price target of $39.79 is a 207.3% premium to current trading levels.

Short sellers, on the other hand, have been actively targeting Intellia Therapeutics. Short interest jumped 20.3% in the two most recent reporting periods to a record 7.41 million shares. This represents a healthy 23.8% of NTLA's available float, or 11.9 times the average daily pace of trading.


a schaeffer's exclusive

5 NEW STOCK PICKS

We're celebrating 38 years with this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Market-Moving Event Just 60 Days Away
This analyst predicts a major market moving event happening as soon as August 13.
Chinese Stock Swings Higher on Buyout Bid
Ritter Pharmaceuticals stock is among the worst on the Nasdaq today
Stocks Grab Another Weekly Win as Trade Picture Brightens
Stocks spent most of the week in positive territory
The Market-Moving Event Just 60 Days Away
This analyst predicts a major market moving event happening as soon as August 13.